A. Bizieux

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study

Hugues Bourgeois, Françoise Grudé, P. Solal-Céligny et al. · Annals of Oncology · 2017 · 51 citations · Full text

Medicine, Oncology, Palliative Care +9

Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?

M. Marcq, Audrey Vallée, A. Bizieux et al. · Journal of Thoracic Oncology · 2014 · 20 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

J.B. Auliac, C. Chouaïd, L. Greiller et al. · Lung Cancer · 2014 · 20 citations

Medicine, Oncology, Pharmacology +9

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

J.B. Auliac, Charles Fournier, Clarisse Audigier-Valette et al. · Targeted Oncology · 2015 · 18 citations

Medicine, Oncology, Pharmacotherapy +11

Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC ^‡ 04-2017)

A. Vergnenègre, I. Monnet, A. Bizieux et al. · Future Oncology · 2020 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17